Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients

Epilepsy and Behavior

Volumn 23, Issue 4, 2012, Pages 497-499

  Kim, Dong Wook ^a   Yoo, Moon Won ^a   Park, Kyoung Sik ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

Epilepsy; Leptin; Weight loss; Zonisamide

Indexed keywords

LEPTIN; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LIPID ANALYSIS; MONOTHERAPY; OBESITY; OBSERVATIONAL STUDY; OPEN STUDY; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; EPILEPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; LEPTIN; LINEAR MODELS; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; WEIGHT LOSS; YOUNG ADULT;

EID: 84862799400     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.11.024     Document Type: Article

References (14)

1. Sheth R.D. Metabolic concerns associated with antiepileptic medications. Neurology 2004, 63:S24-S29.
2. Ben-Menachem E. Weight issues for people with epilepsy-a review. Epilepsia 2007, 48(Suppl. 9):42-45.
3. Bray G.A., Hollander P., Klein S., et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003, 11:722-733.
4. Ben-Menachem E., Axelsen M., Johanson E.H., Stagge A., Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003, 11:556-562.
5. Faught E., Ayala R., Montouris G.G., Leppik I.E. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001, 57:1774-1779. Zonisamide 922 Trial Group.
6. Gadde K.M., Franciscy D.M., Wagner H.R., Krishnan K.R. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003, 289:1820-1825.
7. Verrotti A., la Torre R., Trotta D., Mohn A., Chiarelli F. Valproate-induced insulin resistance and obesity in children. Horm Res 2009, 71:125-131.
8. Aydin K., Serdaroglu A., Okuyaz C., Bideci A., Gucuyener K. Serum insulin, leptin, and neuropeptide y levels in epileptic children treated with valproate. J Child Neurol 2005, 20:848-851.
9. Greco R., Latini G., Chiarelli F., Iannetti P., Verrotti A. Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005, 65:1808-1809.
10. Theisen F.M., Beyenburg S., Gebhardt S., et al. A prospective study of body weight and serum leptin levels in patients treated with topiramate. Clin Neuropharmacol 2008, 31:226-230.
11. Park S.P., Kim S.Y., Hwang Y.H., Lee H.W., Suh C.K., Kwon S.H. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007, 3:175-180.
12. Wellmer J., Wellmer S., Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009, 119:233-238.
13. Rodriguez A., Catalan V., Gomez-Ambrosi J., Fruhbeck G. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?. Curr Pharm Des 2007, 13:2169-2175.
14. Ravussin E., Smith S.R., Mitchell J.A., et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 2009, 17:1736-1743.